Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,384 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Hanauer SB, et al. Among authors: wolf d. Gastroenterology. 2006 Feb;130(2):323-33; quiz 591. doi: 10.1053/j.gastro.2005.11.030. Gastroenterology. 2006. PMID: 16472588 Clinical Trial.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. Sandborn WJ, et al. Among authors: wolf dc. Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042. Gastroenterology. 2001. PMID: 11313302 Clinical Trial.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Hanauer SB, et al. Among authors: wolf dc. Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4. Lancet. 2002. PMID: 12047962 Clinical Trial.
Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.
Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Sandborn WJ, et al. Gastroenterology. 2003 Aug;125(2):380-8. doi: 10.1016/s0016-5085(03)00877-1. Gastroenterology. 2003. PMID: 12891539 Clinical Trial.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Rutgeerts P, et al. Among authors: wolf dc. Gastroenterology. 2004 Feb;126(2):402-13. doi: 10.1053/j.gastro.2003.11.014. Gastroenterology. 2004. PMID: 14762776 Clinical Trial.
Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Sands BE, et al. Among authors: wolf dc. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. N Engl J Med. 2004. PMID: 14985485 Clinical Trial.
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Rutgeerts P, et al. Gastrointest Endosc. 2006 Mar;63(3):433-42; quiz 464. doi: 10.1016/j.gie.2005.08.011. Gastrointest Endosc. 2006. PMID: 16500392 Clinical Trial.
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Sands BE, et al. J Clin Gastroenterol. 2006 Jul;40(6):482-9. doi: 10.1097/00004836-200607000-00005. J Clin Gastroenterol. 2006. PMID: 16825929 Clinical Trial.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Targan SR, et al. Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21. Gastroenterology. 2007. PMID: 17484865 Clinical Trial.
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Sandborn WJ, et al. Among authors: d haens g, wolf dc. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. doi: 10.1016/j.cgh.2010.04.021. Epub 2010 May 6. Clin Gastroenterol Hepatol. 2010. PMID: 20451663 Clinical Trial.
2,384 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback